Novanta Inc. · NASDAQ:NOVT
Novanta — Q1 2026 Earnings Presentation
22 slides from Novanta's earnings presentation, May 12, 2026
Slide 1: A trusted technology partner
A trusted technology partner JANUARY 2026 Confidential 1 and Proprietary
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this presentation are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on current expectations and assumptions that are subject to risks and uncertainties. All statements contained in thi
Slide 3: We accelerate innovation and productivity for leading global OEMs in attractive markets
We accelerate innovation and productivity for leading global OEMs in attractive markets BUSINESS MODEL FOCUS FINANCIAL PROFILE ~$975M Differentiated long-term OEM supplier Revenue Win in high-growth end ~$222M markets, with leading OEMs Adjusted EBITDA +22% of sales ~55% Sole-source customized
Slide 4: Novanta's growth runs on self-sustaining momentum
Novanta’s growth runs on self-sustaining momentum 1 Win in high-growth markets Grow Innovate & expand with organic revenue attractive growth platforms Novanta Make cash-accretive 3 Growth acquisitions in adjacent areas: Evolve System business mix 2 Select asset-light businesses • Medical technologie
Slide 5: We're entering the next phase in our transformation journey
We’re entering the next phase in our transformation journey +Medical Revenue +Subsystems Growth +Recurring Advanced Consumables Industrial Subsystems ~4X Revenue +Embedded Growth Software Medical Advanced Components 2012 Sales 2024 Sales 2030 Direction 2012 Sales 2024 Sales 2030 Direction Expanding
Slide 6: We're pursuing innovative growth platforms in attractive markets
We’re pursuing innovative growth platforms in +$4B attractive markets of additional market opportunity by 2030 Precision Scan Physical Robotic Pumps & Medicine Systems AI Surgery Insufflators Confidential 6 and Proprietary
Slide 7: Expanding our market leadership in gas and fluid management
Expanding our market leadership in gas and fluid management WHY NOVANTA WINS • Market leader in smoke evacuation insufflation • Proprietary algorithms and sensing in fluid & flow management • Expanding into arthroscopy pumps with same customers SMART PUMPS integrated smoke evacuation and insufflatio
Slide 8: We've established a strong capability as a supplier of medical consumables
We’ve established a strong capability as a supplier of medical consumables WHY NOVANTA WINS • Current product offerings have grown to become ~15% of company sales • Strong manufacturing and engineering competency • Seen by our partners as a good supplier, creating a MEDICAL good pedestal to jump off
Slide 9: We're a leading supplier for robotic surgery applications
We’re a leading supplier for robotic surgery applications FLUID/GAS MANAGEMENT SOLUTIONS WHY NOVANTA WINS • Customized unique solutions, partnering with multiple OEMs • Insufflation leadership, integrated with surgical robot PRECISION systems MOTION for robotic • Position and force/torque sensing, a
Slide 10: Our proprietary physical AI robotics solutions are focused on advanced safety and sensing
Our proprietary physical AI MOTION CONTROL robotics solutions are focused precise motion via miniaturized drives, on advanced safety and sensing custom motors & mechatronics WHY NOVANTA WINS • Integrated safety with best-in-class dexterity • Compact and lightweight, with high power efficiency • Uniq
Slide 11: Our solutions drive productivity, support early disease detection, and improve patient outcomes
Our solutions drive productivity, PRECISION MOTION sample movement support early disease detection, & alignment and improve patient outcomes RFID READER reagent & sample tracking MACHINE VISION WHY NOVANTA WINS sample scanning & analysis • Supporting clinical adoption of advanced multi- LIGHT ENGINE
Slide 12: High-performance culture is our competitive advantage
High-performance culture is our competitive advantage COHESIVE ENGAGED TEAMS EMPLOYEES Diverse, inclusive, Engage around collaborative – a shared vision committed to win & purpose M&A Talent Owner & Capital Novanta NOVANTA Mindset Allocation Leverage WAY CULTURE Business units with Scale agility, sp
Slide 13: We compound cash flows through attractive acquisitions
We compound cash flows through attractive acquisitions ACQUISITION TRACK RECORD $1.2B 21 Deploy High- cash into ~ cash-flow acquisitions businesses Capital deployed Transactions HOW WE COMPOUND LONG-TERM ACQUISITION PIPELINE Target gross leverage less than 3.0x +$15B Aggregate revenue Disciplined ca
Slide 14: And we deliver consistently strong financial results
And we deliver consistently strong financial results REVENUE ADJUSTED EBITDA FINANCIAL FRAMEWORK $225M to $222M Mid- to high-single-digit $978M to $975M $210M organic growth $949M Double-digit reported +14% growth through +12% CAGR acquisitions CAGR 100 bps per year of gross margin expansion $244M S
Slide 15: Our near-term momentum is accelerating
Our near-term momentum is accelerating STRONG INNOVATION CUSTOMER MANUFACTURING HEALTHY M&A ORDER BOOK PIPELINE WINS REGIONALIZATION PIPELINE Sequential $50M incremental Strong Design Win On track Focus on medical, revenue growth new product sales in growth in our target for trade consumables moment
Slide 16: We deliver innovation that matters
We deliver innovation that matters Confidential 16 and Proprietary
Slide 17: Use of non-GAAP measures
Use of non-GAAP measures The non-GAAP financial measures used in this presentation are Adjusted EBITDA and Adjusted Gross Profit Margin. The Company believes that these non-GAAP financial measures provide useful and supplementary information to investors regarding the operating performance of the Co
Slide 18: Non-GAAP reconciliation
Non-GAAP reconciliation NINE MONTHS TWELVE MONTHS ENDED ENDED (in thousands of dollars) Dec 31, Dec 31, Dec 31, Dec 31, Dec 31, Dec 31, Dec 31, Dec 31, Dec 31, Dec 31, Dec 31, Dec 31, Dec 31, Sep 26, 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 REVENUE Revenue (GAAP) $243,79
Slide 19: Our businesses align to end-market growth themes
Our businesses align to end-market growth themes PRECISION ROBOTICS AND ADVANCED PRECISION MANUFACTURING AUTOMATION SURGERY MEDICINE Key Applications Advanced material Metal-based Factory, warehouse & Medical & Robotic surgery Minimally invasive Genomics, In vitro diagnostics processing additive lab
Slide 20: We help automate & optimize manufacturing through advanced beam steering
We help automate & optimize manufacturing through advanced beam steering WHY NOVANTA WINS • Never-before possible throughput, precision & miniaturization EXAMPLE • Proprietary integrated solution APPLICATIONS: of hardware and software Laser Additive Manufacturing, Micromachining, and Ophthalmology •
Slide 21: Revenue segmentation
Revenue segmentation Advanced Modules Robotics & Minimally Invasive Intelligent & Robotic Surgery ~55% Growth profile: MSD Automation Equipment Margin profile: $$$ ~35% ~20% End Product Markets(1) Types(2) ~15% Advanced ~10% Manufacturing ~15% Non-invasive ~30% ~10% ~10% MedTech Intelligent (IVD, Op
Slide 22: Mandatory Convertible Preferred Equity Offering Completed
Mandatory Convertible Preferred Equity Offering Completed OFFERING DETAILS OFFERING RATIONALE Tangible Equity Unit Security (category of Mandatory Convertible Preferred) Fundamentally, a mandatory offering is intended to issue stock at a premium to the market, with a yield Offering Size $632.5 milli